
    
      It is hypothesized that (1) the raltegravir regimen will have similar efficacy in terms of
      both viral suppression as well as increases in CD4 cell counts and (2) raltegravir will have
      significantly less impact on plasma lipids, lipoproteins and lipoproteins subtypes, compared
      with lopinavir/ritonavir.
    
  